Recently, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP.2 strain of SARS-CoV-2. The updated mRNA COVID-19 vaccines target currently circulating variants more closely and provide better protection against severe outcomes, including hospitalization and death. These actions relate to updated mRNA COVID-19 vaccines manufactured by ModernaTX Inc. and Pfizer Inc.
However, In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines. Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible – Read more.
Recently, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a...
Pfizer introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across th...
Basel, Switzerland- Roche is one step closer to gaining FDA approval for Xolair® (omalizumab). The agency accepts its supplemental Biologics License Application (sBLA) un...
Falling vaccination rates throughout Europe are leading to an increase in infections such as measles and rubella and Europe fears new epidemics. Measles viruses, for inst...
New York- Pfizer Inc. has announced promising topline data from its Phase 2b clinical trial (NCT04707313) evaluating the oral Glucagon-like peptide-1 receptor agonist (GL...
• Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. • Grünenthal is running a gl...
A virtual marketplace leading your business into the future
